Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Organogenesis ORGO

Healthcare  —  Drug Manufacturers Specialty & Generic
1.41 (0.01) (0.70%) as of 25 Sep
Market cap
$207.1M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Organogenesis (ORGO) Business Profile

Updated before January 2025

Company Overview

Organogenesis Holdings Inc. (NASDAQ: ORGO) is a leading regenerative medicine company specializing in advanced wound care and surgical and sports medicine solutions. Founded in 1985 and headquartered in Canton, Massachusetts, Organogenesis has grown to become a key player in the field of regenerative medicine. The company was initially established to develop and commercialize products based on living cell technologies. Over the years, it has expanded its portfolio to include a wide range of products that address unmet medical needs in wound care and surgical applications.

Organogenesis is led by a team of experienced executives. Gary S. Gillheeney, Sr. serves as the President and Chief Executive Officer, bringing decades of experience in the healthcare and biotechnology sectors. The leadership team is committed to driving innovation and delivering high-quality solutions to improve patient outcomes.

Core Business Segments

Organogenesis operates through two primary business segments: Advanced Wound Care and Surgical & Sports Medicine. Each segment offers a diverse range of products designed to address specific medical needs.

Advanced Wound Care

This segment focuses on providing solutions for chronic and acute wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers. Key products include:

  • Apligraf®: A bioengineered living cell therapy designed to treat venous leg ulcers and diabetic foot ulcers. It mimics human skin and promotes healing by delivering living cells, growth factors, and an extracellular matrix.
  • Dermagraft®: A regenerative tissue product used for the treatment of diabetic foot ulcers. It is composed of living fibroblasts and a bioabsorbable scaffold.
  • PuraPly® AM: An antimicrobial wound management product that helps reduce bioburden and supports wound healing.
  • NuShield®: A dehydrated placental tissue allograft used for wound covering and healing.

Surgical & Sports Medicine

This segment provides regenerative and surgical solutions for orthopedic, spine, and sports medicine applications. Key products include:

  • Affinity®: A cryopreserved amniotic membrane used in surgical applications to reduce inflammation and promote healing.
  • NuCel®: A cellular allograft designed to support bone repair and regeneration.
  • ReNu®: A cryopreserved amniotic suspension allograft used in sports medicine to treat joint pain and inflammation.
  • TransCyte®: A temporary skin substitute used in burn care and other surgical applications.

Business Model

Organogenesis operates on a vertically integrated business model, which allows the company to control every aspect of its product lifecycle, from research and development to manufacturing and commercialization. This approach ensures high-quality standards and cost efficiency.

The company generates revenue primarily through the sale of its advanced wound care and surgical products. It also collaborates with healthcare providers, hospitals, and clinics to deliver tailored solutions that meet specific patient needs. Organogenesis invests heavily in research and development to maintain its competitive edge and expand its product portfolio.

Strategic Direction

Organogenesis is focused on driving growth through innovation, market expansion, and operational excellence. Key strategic priorities include:

  • Product Innovation: The company aims to develop new regenerative medicine products and enhance existing ones to address a broader range of medical conditions.
  • Market Expansion: Organogenesis is working to expand its presence in international markets, particularly in Europe and Asia, to tap into growing demand for advanced wound care and surgical solutions.
  • Sustainability Goals: The company is committed to reducing its environmental footprint by adopting sustainable manufacturing practices and minimizing waste.
  • Digital Transformation: Organogenesis is leveraging digital technologies to improve operational efficiency and enhance customer engagement.

Competitive Landscape

Organogenesis operates in a highly competitive market, facing competition from both established players and emerging companies in the regenerative medicine and advanced wound care sectors. Key competitors include:

  • Integra LifeSciences: A global leader in medical technologies, offering a range of wound care and surgical solutions.
  • MiMedx Group: Specializes in placental tissue allografts for wound care and surgical applications.
  • Smith & Nephew: A multinational medical equipment company with a strong presence in advanced wound care and orthopedic products.
  • Acelity (now part of 3M): Known for its negative pressure wound therapy systems and advanced wound dressings.

Risk Factors

Organogenesis faces several risks that could impact its business operations and financial performance. Key risk factors include:

  • Market Dependence: The company relies heavily on the success of its advanced wound care and surgical products. Any decline in demand for these products could adversely affect revenue.
  • Regulatory Challenges: As a healthcare company, Organogenesis must comply with stringent regulatory requirements. Delays or failures in obtaining regulatory approvals could hinder product launches.
  • Supply Chain Disruptions: The company depends on a reliable supply chain for raw materials and manufacturing. Disruptions due to geopolitical events, natural disasters, or pandemics could impact production.
  • Competition: Intense competition in the regenerative medicine market could pressure pricing and market share.

Recent Developments

Organogenesis has made significant strides in recent years to strengthen its market position and drive innovation. Recent developments include:

  • New Product Launches: The company introduced several new products, including advanced wound care solutions and surgical allografts, to address unmet medical needs.
  • Strategic Partnerships: Organogenesis has entered into collaborations with healthcare providers and research institutions to advance regenerative medicine technologies.
  • Operational Expansion: The company has expanded its manufacturing facilities to meet growing demand and improve supply chain resilience.
  • COVID-19 Impact: While the pandemic posed challenges, Organogenesis adapted by implementing safety measures and leveraging digital tools to maintain business continuity.

Investment Considerations

Investors considering Organogenesis should weigh the following strengths and risks:

Strengths

  • Market Leadership: Organogenesis is a recognized leader in regenerative medicine, with a strong portfolio of innovative products.
  • Growth Potential: The company operates in a growing market driven by increasing demand for advanced wound care and surgical solutions.
  • R&D Focus: Organogenesis invests heavily in research and development, ensuring a steady pipeline of new products.

Risks

  • Regulatory Uncertainty: The healthcare industry is subject to complex regulations, which could impact product approvals and market access.
  • Competitive Pressure: Intense competition could affect pricing and profitability.
  • Economic Conditions: Macroeconomic factors, such as healthcare budget constraints, could impact demand for Organogenesis products.

Conclusion

Organogenesis is well-positioned to capitalize on the growing demand for regenerative medicine solutions. With a strong product portfolio, a commitment to innovation, and a focus on operational excellence, the company is poised for long-term growth. However, investors should remain mindful of the risks associated with regulatory challenges, competition, and market dependence. Overall, Organogenesis represents a compelling opportunity for those seeking exposure to the regenerative medicine sector.